Novartis will announce new evidence on Cosentyx for psoriatic arthritis

[Fred]

Novartis will be presenting new evidence for the use of Cosentyx for psoriatic arthritis at the November 2017 ACR/ARHP Annual Meeting.

Quote:

---

New evidence on the efficacy of the innovative biologic Cosentyx® (secukinumab) demonstrating its potential to reduce structural disease progression in patients with specific rheumatological conditions will be presented at the 2017 ACR/ARHP Annual Meeting in San Diego, United States. The Cosentyx late breaking presentations will include new 4-year data from the MEASURE 1 study in patients with ankylosing spondylitis (AS), and 24-week data from the FUTURE 5 study in patients with psoriatic arthritis (PsA), two debilitating autoimmune diseases with a high risk of mobility loss.

"Maintaining mobility is our hope and vision for every patient with chronic inflammatory diseases such as AS and PsA." said Vas Narasimhan, Global Head, Drug Development and Chief Medical Officer, Novartis. "Reducing radiographic progression would be a strong signal for patients who hope to stay mobile as this would result in a significant improvement of their quality of life."

Source: novartis.com